Small-molecule Ro-08-2750 interacts with many RNA-binding proteins and elicits MUSASHI2-independent phenotypes

  1. Neelanjan Mukherjee1,2
  1. 1Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
  2. 2RNA Bioscience Initiative, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
  3. 3Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland
  4. 4Howard University Karsh STEM Scholars Program, Washington DC 20059, USA
  1. Corresponding author: neelanjan.mukherjee{at}cuanschutz.edu

Abstract

RNA-binding proteins (RBPs) are key regulators of gene expression. Small molecules targeting these RBP–RNA interactions are a rapidly emerging class of therapeutics for treating a variety of diseases. Ro-08-2750 (Ro) is a small molecule identified as a competitive inhibitor of Musashi (MSI)–RNA interactions. Here, we show that multiple Ro-dependent cellular phenotypes, specifically adrenocortical steroid production and cell viability, are Musashi-2 (MSI2)-independent. Using an unbiased proteome-wide approach, we discovered Ro broadly interacts with RBPs, many containing RRM domains. To confirm this finding, we leveraged the large-scale ENCODE data to identify a subset of RBPs whose depletion phenocopies Ro inhibition, indicating Ro is a promiscuous inhibitor of multiple RBPs. Consistent with broad disruption of ribonucleoprotein complexes, Ro treatment leads to stress granule formation. This strategy represents a generalizable framework for validating the specificity and identifying targets of RBP inhibitors in a cellular context.

Keywords

  • Received January 20, 2023.
  • Accepted June 13, 2023.

This article, published in RNA, is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

Articles citing this article

| Table of Contents
OPEN ACCESS ARTICLE